New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:55 EDTBTX, CUR, ASTM, STEM, GERN, OSIRSupreme Court turns down appeal over stem cell research, SCOTUSblog says
The Supreme Court turned down an appeal by scientists seeking to stop all studies on embryonic stem cells, according to SCOTUSblog. The Fly notes that companies engaged in the research, development, and commercialization of stem cell therapies include StemCells (STEM), Neuralstem (CUR), Aastrom Biosciences (ASTM) and Osiris Therapeutics (OSIR). Also, earlier this morning, BioTime (BTX) entered into an agreement to acquire the intellectual property, including patents and patent applications, and other assets related to Geron's (GERN) human embryonic stem cell programs. Reference Link
News For STEM;CUR;OSIR;ASTM;BTX;GERN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
18:48 EDTGERNOn The Fly: After Hours Movers
UP AFTER EARNINGS: Lam Research (LRCX), up 9.2%... Fortinet (FTNT), up 9%. ALSO HIGHER: Lumber Liquidators (LL), up 2% after being initiated with a Buy, $45 target at Cantor... Geron (GERN), up 2.2% after being initiated with an Outperform at Oppenheimer... Applied Materials (AMAT), up 1.6% after Lam Research reported quarterly results. DOWN AFTER EARNINGS: Sanmina (SANM), down 10.5%... IBM (IBM), down marginally... Rambus (RMBS), down 3.7%.
16:31 EDTGERNGeron initiated with an Outperform at Oppenheimer
Subscribe for More Information
12:01 EDTBTXOncoCyte announces initial data from ongoing clinical study of PanC-Dx
BioTime and its subsidiary OncoCyte Corporation announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx, OncoCyte’s non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X in distinguishing patients with malignant breast lesions from those with negative findings. The controlled study, initiated at Scottsdale Medical Imaging Laboratories in Scottsdale, AZ, is ongoing and has nearly completed enrollment of over 600 patients. The goal of this study is to assess the performance of PanC-Dx in discriminating patients with malignant breast lesions from those with negative findings or benign findings. Early data showed that PanC-Dx™ identified a mean concentration of COL10A1 protein in sera of breast cancer patients that was 35% higher than the mean COL10A1 value in sera of normal individuals (n=32). No significant differences were noted when comparing breast cancer patients to patients with confirmed benign disease suggesting that additional biomarkers may be necessary to discriminate these two populations.
06:32 EDTBTXBioTime and its subsidiary announce positive results from PanC-Dx studies
Subscribe for More Information
April 17, 2015
08:33 EDTOSIROsiris management to meet with Brean Capital
Subscribe for More Information
April 16, 2015
08:13 EDTSTEMStemCells completes enrollment in first cohort of Phase II Pathway Study
StemCells announced that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study. The first cohort is an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study. The second cohort of the study is a single-blind arm in 40 patients that will assess efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of cervical spinal cord injury.
April 9, 2015
08:03 EDTOSIROsiris names Alla Danilkovitch as Chief Scientific Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use